No title
Women’s access to essential medicines is restricted by intersecting barriers such as economic dependence, reproductive health stigma, information gaps, and pharmaceutical R&D priorities that overlook their needs. Access to medicines is simultaneously shaped by international intellectual property law, particularly patent protection under the TRIPS Agreement, which has been criticised for restri
